Welcome to LookChem.com Sign In|Join Free
  • or
2,8-BIS(TRIFLUOROMETHYL)-4-BROMOQUINOLINE is a specific chemical compound that belongs to the class of orgo-halogen compounds known as 4-bromoquinolines. It features a quinoline ring system with two trifluoromethyl groups and a bromine atom placed in the 4th position. 2,8-BIS(TRIFLUOROMETHYL)-4-BROMOQUINOLINE is often used in organic synthesis and may play a role in creating more complex chemical structures. Its exact properties can be precisely determined by techniques such as nuclear magnetic resonance (NMR), infrared spectroscopy (IR), and mass spectrometry (MS).

35853-45-3

Post Buying Request

35853-45-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

35853-45-3 Usage

Uses

Used in Organic Synthesis:
2,8-BIS(TRIFLUOROMETHYL)-4-BROMOQUINOLINE is used as a building block for the synthesis of more complex chemical structures. Its unique arrangement of bromine and fluorine atoms, along with specific carbon and hydrogen arrangements, makes it a valuable component in the creation of new molecules with potential applications in various fields.
Used in Pharmaceutical Industry:
2,8-BIS(TRIFLUOROMETHYL)-4-BROMOQUINOLINE is used as a key intermediate in the synthesis of pharmaceutical compounds. Its presence in the structure of certain drugs can contribute to their therapeutic effects, making it an essential component in the development of new medications.
Used in Chemical Research:
2,8-BIS(TRIFLUOROMETHYL)-4-BROMOQUINOLINE is used as a research compound in academic and industrial laboratories. Its properties and reactivity can be studied to gain insights into the behavior of similar compounds and to develop new synthetic methods and applications.

Check Digit Verification of cas no

The CAS Registry Mumber 35853-45-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,8,5 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 35853-45:
(7*3)+(6*5)+(5*8)+(4*5)+(3*3)+(2*4)+(1*5)=133
133 % 10 = 3
So 35853-45-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H4BrF6N/c12-7-4-8(11(16,17)18)19-9-5(7)2-1-3-6(9)10(13,14)15/h1-4H

35853-45-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-bromo-2,8-bis(trifluoromethyl)quinoline

1.2 Other means of identification

Product number -
Other names 4-bromo-2,8-bistrifluoromethylquinoline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:35853-45-3 SDS

35853-45-3Synthetic route

2,8-bis(trifluoromethyl)quinolin-4-ol
35853-41-9

2,8-bis(trifluoromethyl)quinolin-4-ol

(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

Conditions
ConditionsYield
With phosphorus(V) oxybromide99%
With phosphorus(V) oxybromide at 120℃; for 5h; Inert atmosphere;98%
With phosphorus(V) oxybromide at 140℃; Inert atmosphere;98%
2,8-bis(trifluoromethyl)quinolin-4-yl 4-methylbenzenesulfonate
150785-70-9

2,8-bis(trifluoromethyl)quinolin-4-yl 4-methylbenzenesulfonate

(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

Conditions
ConditionsYield
With phosphorus; bromine In acetic acid at 25℃; for 4h;80%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

N-benzhydryl 3-azetidinone
40320-60-3

N-benzhydryl 3-azetidinone

3-(2,8-bis(trifluoromethyl)-4-quinolinyl)-1-diphenylmethyl-3-azetidinol
260972-91-6

3-(2,8-bis(trifluoromethyl)-4-quinolinyl)-1-diphenylmethyl-3-azetidinol

Conditions
ConditionsYield
With n-butyllithium In water100%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

para-thiocresol
106-45-6

para-thiocresol

2,8-bis(trifluoromethyl)-4-quinolyl p-tolylsulphide
177092-30-7

2,8-bis(trifluoromethyl)-4-quinolyl p-tolylsulphide

Conditions
ConditionsYield
With potassium hydroxide In methanol; ethanol at 60℃; for 2h;95%
ferrocenecarboxaldehyde
12093-10-6

ferrocenecarboxaldehyde

(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

[2,8-bis(trifluoromethyl)quinolin-4-yl]ferrocenemethanol

[2,8-bis(trifluoromethyl)quinolin-4-yl]ferrocenemethanol

Conditions
ConditionsYield
Stage #1: (2,8-bis-trifluoromethyl)-4-bromoquinoline With n-butyllithium In diethyl ether; hexane at -78℃; for 0.333333h; Inert atmosphere; Schlenk technique;
Stage #2: ferrocenecarboxaldehyde In diethyl ether; hexane at -78℃; for 2h; Inert atmosphere; Schlenk technique;
94%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

sodium vinyl trifluoroborate

sodium vinyl trifluoroborate

2,8-bis(trifluoromethyl)-4-vinylquinoline
1031928-53-6

2,8-bis(trifluoromethyl)-4-vinylquinoline

Conditions
ConditionsYield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2 Suzuki Coupling;94%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

copper(I) cyanide
544-92-3

copper(I) cyanide

2,8-bis(trifluoromethyl)quinoline-4-carbonitrile

2,8-bis(trifluoromethyl)quinoline-4-carbonitrile

Conditions
ConditionsYield
In N,N-dimethyl-formamide Substitution; Heating;93%
piperazine
110-85-0

piperazine

(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

4-(piperazin-1-yl)-2,8-bis(trifluoromethyl)quinoline

4-(piperazin-1-yl)-2,8-bis(trifluoromethyl)quinoline

Conditions
ConditionsYield
With potassium carbonate; triethylamine at 135℃; for 4h;92%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

1-acetoxy-1'-(1,3-dioxan-2-yl)ferrocene
1241848-96-3

1-acetoxy-1'-(1,3-dioxan-2-yl)ferrocene

1-(1,3-dioxan-2-yl)-1'-(2,8-bis(trifluoromethyl)quinolin-4-yloxy)-ferrocene
1381984-20-8

1-(1,3-dioxan-2-yl)-1'-(2,8-bis(trifluoromethyl)quinolin-4-yloxy)-ferrocene

Conditions
ConditionsYield
Stage #1: 1-acetoxy-1'-(1,3-dioxan-2-yl)ferrocene With sodium methylate In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere; Schlenk technique;
Stage #2: (2,8-bis-trifluoromethyl)-4-bromoquinoline In N,N-dimethyl-formamide at 150℃; for 6h; Inert atmosphere; Schlenk technique;
92%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

carbon dioxide
124-38-9

carbon dioxide

2,8-bis-(trifluoromethyl)-quinoline-4-carboxylic acid
35853-50-0

2,8-bis-(trifluoromethyl)-quinoline-4-carboxylic acid

Conditions
ConditionsYield
With n-butyllithium In diethyl ether at -35℃; for 0.333333h;86%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

4-azido-2,8-bis(trifluoromethyl)quinoline
1258291-33-6

4-azido-2,8-bis(trifluoromethyl)quinoline

Conditions
ConditionsYield
With sodium azide In N,N-dimethyl-formamide at 90℃; for 1h;85%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

vinylboronic acid dibutyl ester
6336-45-4

vinylboronic acid dibutyl ester

2,8-bis(trifluoromethyl)-4-vinylquinoline
1031928-53-6

2,8-bis(trifluoromethyl)-4-vinylquinoline

Conditions
ConditionsYield
With tetrakis(triphenylphosphine) palladium(0); potassium hydroxide In water; toluene for 24h; Suzuki-Miyaura coupling; Inert atmosphere; Reflux;82%
With potassium hydroxide; tetrakis(triphenylphosphine) palladium(0) In water; toluene for 24h; Suzuki-Miyaura cross-coupling reaction; Inert atmosphere; Reflux;82%
With potassium hydroxide; tetrakis(triphenylphosphine) palladium(0) In water; toluene for 24h; Suzuki-Miyaura cross-coupling reaction; Inert atmosphere; Reflux;82%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

propargyl alcohol
107-19-7

propargyl alcohol

3-(2,8-bis(trifluoromethyl)quinolin-4-yl)prop-2-yn-1-ol

3-(2,8-bis(trifluoromethyl)quinolin-4-yl)prop-2-yn-1-ol

Conditions
ConditionsYield
Stage #1: propargyl alcohol With triethylamine for 0.0833333h; Sonogashira Cross-Coupling; Inert atmosphere;
Stage #2: (2,8-bis-trifluoromethyl)-4-bromoquinoline With bis-triphenylphosphine-palladium(II) chloride; copper(l) iodide for 4h; Reflux;
80%
3-hydroxypiperazine
6859-99-0

3-hydroxypiperazine

(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

4-(3-hydroxypiperidine-1-yl)-2,8-bis(trifluoromethyl)quinoline
1092355-84-4

4-(3-hydroxypiperidine-1-yl)-2,8-bis(trifluoromethyl)quinoline

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 120℃; for 2h;78%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

ruthenocene carboxylaldheyde
66507-25-3

ruthenocene carboxylaldheyde

[2,8-bis(trifluoromethyl)quinolin-4-yl]ruthenocenemethanol

[2,8-bis(trifluoromethyl)quinolin-4-yl]ruthenocenemethanol

Conditions
ConditionsYield
Stage #1: (2,8-bis-trifluoromethyl)-4-bromoquinoline With n-butyllithium In diethyl ether; hexane at -78℃; for 0.333333h; Inert atmosphere; Schlenk technique;
Stage #2: ruthenocene carboxylaldheyde In diethyl ether; hexane at -78℃; for 2h; Inert atmosphere; Schlenk technique;
78%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

(E)-2-(6-(4,4,5,5-tetramethylmethyl-1,3,2-dioxaborolan-2-yl)-hex-5-en-1-yl)isoindoline-1,3-dione

(E)-2-(6-(4,4,5,5-tetramethylmethyl-1,3,2-dioxaborolan-2-yl)-hex-5-en-1-yl)isoindoline-1,3-dione

(E)-2-(6-(2,8-bis(trifluoromethyl)quinolin-4-yl)hex-5-en-1-yl)isoindoline-1,3-dione

(E)-2-(6-(2,8-bis(trifluoromethyl)quinolin-4-yl)hex-5-en-1-yl)isoindoline-1,3-dione

Conditions
ConditionsYield
With palladium diacetate; caesium carbonate; XPhos In tetrahydrofuran; water for 5h; Suzuki Coupling; Reflux; Inert atmosphere;77%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

C20H26BNO4

C20H26BNO4

C25H18F6N2O2

C25H18F6N2O2

Conditions
ConditionsYield
With palladium diacetate; caesium carbonate; XPhos In tetrahydrofuran; water Reflux;77%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

bis(2,8-bis-trifluoromethyl quinolyl) disulphide
736147-22-1

bis(2,8-bis-trifluoromethyl quinolyl) disulphide

Conditions
ConditionsYield
With potassium ethyldithiocarbamate In DMF (N,N-dimethyl-formamide) at 20℃; for 10h;75%
With potassium ethyldithiocarbamate In DMF (N,N-dimethyl-formamide) at 20℃; for 10h;75%
pyrrolidin-3-ol
40499-83-0

pyrrolidin-3-ol

(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

4-(3-hydroxypyrrolidin-1-yl)-2,8-bis(trifluoromethyl)quinoline
1092355-83-3

4-(3-hydroxypyrrolidin-1-yl)-2,8-bis(trifluoromethyl)quinoline

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 120℃; for 2h;75%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

tri-n-butyl(vinyl)tin
7486-35-3

tri-n-butyl(vinyl)tin

2,8-bis(trifluoromethyl)-4-vinylquinoline
1031928-53-6

2,8-bis(trifluoromethyl)-4-vinylquinoline

Conditions
ConditionsYield
With bis-triphenylphosphine-palladium(II) chloride; tetrabutylammomium bromide; potassium carbonate In acetonitrile at 90℃; for 4h; Stille coupling; Inert atmosphere; Sealed tube;75%
With tetrabutylammomium bromide; potassium carbonate; bis-triphenylphosphine-palladium(II) chloride In acetonitrile at 90℃; for 4h; Product distribution / selectivity; Stille Coupling; Inert atmosphere; Sealed tube;75%
With tetrabutylammomium bromide; potassium carbonate; bis(triphenylphosphine)palladium(II) dichloride In acetonitrile at 90℃; for 4h; Product distribution / selectivity; Stille Coupling reaction; Inert atmosphere;75%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

potassium vinyltrifluoroborate

potassium vinyltrifluoroborate

2,8-bis(trifluoromethyl)-4-vinylquinoline
1031928-53-6

2,8-bis(trifluoromethyl)-4-vinylquinoline

Conditions
ConditionsYield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; caesium carbonate In tetrahydrofuran; water for 24h; Suzuki-Miyaura coupling; Inert atmosphere; Reflux;71%
With caesium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2 In tetrahydrofuran; water for 24h; Inert atmosphere; Reflux;71%
With caesium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2 In tetrahydrofuran; water for 24h; Product distribution / selectivity; Stille Coupling reaction; Inert atmosphere; Reflux;71%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

N-(5-hexenyl)phthalimide
52898-33-6

N-(5-hexenyl)phthalimide

C25H19F6N3O2

C25H19F6N3O2

Conditions
ConditionsYield
With 1,3-bis(2,6-diisopropylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene; palladium diacetate; triethylamine In N,N-dimethyl-formamide at 110℃; Reagent/catalyst;68%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

N-(5-hexenyl)phthalimide
52898-33-6

N-(5-hexenyl)phthalimide

(E)-2-(6-(2,8-bis(trifluoromethyl)quinolin-4-yl)hex-5-en-1-yl)isoindoline-1,3-dione

(E)-2-(6-(2,8-bis(trifluoromethyl)quinolin-4-yl)hex-5-en-1-yl)isoindoline-1,3-dione

Conditions
ConditionsYield
With AD-mix-β; palladium diacetate; triethylamine; 1,3-bis-(2,6-diisopropylphenyl)-imidazol-2-ylidene In N,N-dimethyl-formamide at 110℃; Reagent/catalyst; Inert atmosphere;68%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

benzofuran-2-boronic acid
98437-24-2

benzofuran-2-boronic acid

4-(2-Benzofuranyl)-2,8-bis(trifluoromethyl)quinoline
260972-85-8

4-(2-Benzofuranyl)-2,8-bis(trifluoromethyl)quinoline

Conditions
ConditionsYield
tetrakis(triphenylphosphine) palladium(0) In 1,2-dimethoxyethane; water64%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

N,N-dimethyl-formamide
68-12-2, 33513-42-7

N,N-dimethyl-formamide

2,8-bis(trifluoromethyl)-4-quinoline carboxaldehyde
57120-56-6

2,8-bis(trifluoromethyl)-4-quinoline carboxaldehyde

Conditions
ConditionsYield
With n-butyllithium In tetrahydrofuran; hexane at -78℃;64%
Stage #1: (2,8-bis-trifluoromethyl)-4-bromoquinoline With n-butyllithium In diethyl ether; hexane at -78℃; for 0.5h;
Stage #2: N,N-dimethyl-formamide In diethyl ether; hexane at -78℃; for 3h;
37%
Stage #1: (2,8-bis-trifluoromethyl)-4-bromoquinoline With n-butyllithium In diethyl ether at -78℃;
Stage #2: N,N-dimethyl-formamide In diethyl ether at -78℃;
29%
With n-butyllithium at -78℃; Inert atmosphere;
Stage #1: (2,8-bis-trifluoromethyl)-4-bromoquinoline With n-butyllithium at -78℃; Inert atmosphere;
Stage #2: N,N-dimethyl-formamide Inert atmosphere;
10 g
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

(S)-1-N-Boc-piperidine-2-al
150521-32-7

(S)-1-N-Boc-piperidine-2-al

(S)-tert-butyl 2-((R)-(2,8-bis(trifluoromethyl)quinolin-4-yl)(hydroxy)methyl)piperidine-1-carboxylate
1309854-88-3

(S)-tert-butyl 2-((R)-(2,8-bis(trifluoromethyl)quinolin-4-yl)(hydroxy)methyl)piperidine-1-carboxylate

Conditions
ConditionsYield
Stage #1: (2,8-bis-trifluoromethyl)-4-bromoquinoline With n-butyllithium In diethyl ether at -78℃; for 1h; Inert atmosphere; Schlenk technique;
Stage #2: (S)-1-N-Boc-piperidine-2-al In diethyl ether at -78℃; for 0.333333h; Inert atmosphere; Schlenk technique; stereoselective reaction;
58%
1-phenyl-6-tributylstannyl-3,4-dihydropyrrolo[1,2-a]pyrazine

1-phenyl-6-tributylstannyl-3,4-dihydropyrrolo[1,2-a]pyrazine

(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

1-phenyl-6-(2,8-bis(trifluoromethyl)quinolin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazine

1-phenyl-6-(2,8-bis(trifluoromethyl)quinolin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazine

Conditions
ConditionsYield
With tetrakis(triphenylphosphine) palladium(0); lithium chloride In tetrahydrofuran for 20h; Stille coupling; Heating;56%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

Propargylamine
2450-71-7

Propargylamine

N-(2-propyn-1-yl)-[2,8-bis(trifluoromethyl)]-4-quinolinylamine
1257629-75-6

N-(2-propyn-1-yl)-[2,8-bis(trifluoromethyl)]-4-quinolinylamine

Conditions
ConditionsYield
In 1,4-dioxane Reflux;45%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

4-allyl-1-benzoylpiperidine
155269-97-9

4-allyl-1-benzoylpiperidine

1-benzoyl-4-<(E)-3-<2,8-bis(trifluoromethyl)-4-quinolinyl>allyl>piperidine
155269-98-0

1-benzoyl-4-<(E)-3-<2,8-bis(trifluoromethyl)-4-quinolinyl>allyl>piperidine

Conditions
ConditionsYield
With palladium diacetate; copper(l) iodide; tributyl-amine; triphenyl-o-tolylphosphine In N,N,N,N,N,N-hexamethylphosphoric triamide at 120℃; for 20h;42%
(2,8-bis-trifluoromethyl)-4-bromoquinoline
35853-45-3

(2,8-bis-trifluoromethyl)-4-bromoquinoline

(S,S,p-S)-(-)-1-acetoxy-2-(4-methoxymethyl-1,3-dioxan-2-yl)ferrocene

(S,S,p-S)-(-)-1-acetoxy-2-(4-methoxymethyl-1,3-dioxan-2-yl)ferrocene

(2S,4S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yloxy)-2-(4-methoxymethyl-1,3-dioxan-2-yl)ferrocene

(2S,4S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yloxy)-2-(4-methoxymethyl-1,3-dioxan-2-yl)ferrocene

Conditions
ConditionsYield
Stage #1: (S,S,p-S)-(-)-1-acetoxy-2-(4-methoxymethyl-1,3-dioxan-2-yl)ferrocene With sodium methylate In N,N-dimethyl-formamide at 20℃; for 3h; Inert atmosphere;
Stage #2: (2,8-bis-trifluoromethyl)-4-bromoquinoline In N,N-dimethyl-formamide at 80℃; for 24h; Inert atmosphere;
32%

35853-45-3Relevant academic research and scientific papers

Asymmetric Synthesis of (+)-anti- and (-)-syn-Mefloquine Hydrochloride

Rastelli, Ettore J.,Coltart, Don M.

, p. 9567 - 9575 (2016)

The asymmetric (er > 99:1) total synthesis of (+)-anti- and (-)-syn-mefloquine hydrochloride from a common intermediate is described. The Sharpless asymmetric dihydroxylation is the key asymmetric transformation used in the synthesis of this intermediate. It is carried out on an olefin that is accessed in three steps from commercially available materials, making the overall synthetic sequence very concise. The common diol intermediate derived from the Sharpless asymmetric dihydroxylation is converted into either a trans- or cis-epoxide, and these are subsequently converted to (+)-anti- and (-)-syn-mefloquine, respectively. X-ray crystallographic analysis of derivatives of (+)-anti- and (-)-syn-mefloquine is used to lay to rest a 40 year argument regarding the absolute stereochemistry of the mefloquines. A formal asymmetric (er > 99:1) synthesis of (+)-anti-mefloquine hydrochloride is also presented that uses a Sharpless asymmetric epoxidation as a key step.

Application of 2, 8-bis (trifluoromethyl)-4-hydroxyquinoline derivative in preparation and prevention and treatment of agricultural diseases

-

Paragraph 0355-0358; 0499-0502, (2021/04/07)

The invention discloses application of a 2, 8-bis (trifluoromethyl)-4-hydroxyquinoline derivative in preparation and prevention and treatment of agricultural diseases. Activity test results show that the compound has potential inhibitory activity on four plant pathogenic fungi including sclerotinia sclerotiorum, botrytis cinerea, fusarium graminearum and rhizoctonia solani, and can be developed as a bactericide.

Antifungal Exploration of Quinoline Derivatives against Phytopathogenic Fungi Inspired by Quinine Alkaloids

Chen, Yong-Jia,Ma, Kun-Yuan,Du, Sha-Sha,Zhang, Zhi-Jun,Wu, Tian-Lin,Sun, Yu,Liu, Ying-Qian,Yin, Xiao-Dan,Zhou, Rui,Yan, Yin-Fang,Wang, Ren-Xuan,He, Ying-Hui,Chu, Qing-Ru,Tang, Chen

, p. 12156 - 12170 (2021/10/26)

Enlightened from our previous work of structural simplification of quinine and innovative application of natural products against phytopathogenic fungi, lead structure 2,8-bis(trifluoromethyl)-4-quinolinol (3) was selected to be a candidate and its diversified design, synthesis, and antifungal evaluation were carried out. All of the synthesized compounds Aa1-Db1 were evaluated for their antifungal activity against four agriculturally important fungi, Botrytis cinerea, Fusarium graminearum, Rhizoctonia solani, and Sclerotinia sclerotiorum. Results showed that compounds Ac3, Ac4, Ac7, Ac9, Ac12, Bb1, Bb10, Bb11, Bb13, Cb1. and Cb3 exhibited a good antifungal effect, especially Ac12 had the most potent activity with EC50 values of 0.52 and 0.50 μg/mL against S. sclerotiorum and B. cinerea, respectively, which were more potent than those of the lead compound 3 (1.72 and 1.89 μg/mL) and commercial fungicides azoxystrobin (both >30 μg/mL) and 8-hydroxyquinoline (2.12 and 5.28 μg/mL). Moreover, compound Ac12 displayed excellent in vivo antifungal activity, which was comparable in activity to the commercial fungicide boscalid. The preliminary mechanism revealed that compound Ac12 might cause an abnormal morphology of cell membranes, an increase in membrane permeability, and release of cellular contents. These results indicated that compound Ac12 displayed superior in vitro and in vivo fungicidal activities and could be a potential fungicidal candidate against plant fungal diseases.

Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity

Agnamey, P.,Azas, N.,Cohen, A.,Damiani, C.,Dassonville-Klimpt, A.,Dormoi, J.,Guillon, J.,Marchivie, M.,Pradines, B.,Schneider, J.,Sonnet, P.,Taudon, N.,Tisnerat, C.,Totet, Anne,Mullié, C.

, (2021/11/18)

Malaria is the fifth most lethal parasitic infections in the world. Herein, five new series of aminoalcohol quinolines including fifty-two compounds were designed, synthesized and evaluated in vitro against Pf3D7 and PfW2 strains. Among them, fourteen displayed IC50 values below or near of 50.0 nM whatever the strain with selectivity index often superior to 100.17b was found as a promising antimalarial candidate with IC50 values of 14.9 nM and 11.0 nM against respectively Pf3D7 and PfW2 and a selectivity index higher than 770 whatever the cell line is. Further experiments were achieved to confirm the safety and to establish the preliminary ADMET profile of compound 17b before the in vivo study performed on a mouse model of P. berghei ANKA infection. The overall data of this study allowed to establish new structure-activity relationships and the development of novel agents with improved pharmacokinetic properties.

Synthesis and study of new quinolineaminoethanols as anti-bacterial drugs

Laumaillé, Pierre,Dassonville-klimpt, Alexandra,Peltier, Fran?ois,Mullié, Catherine,Andréjak, Claire,Da-nascimento, Sophie,Castelain, Sandrine,Sonnet, Pascal

, (2019/08/01)

The lack of antibiotics with a novel mode of action associated with the spread of drug resistant bacteria make the fight against infectious diseases particularly challenging. A quinoline core is found in several anti-infectious drugs, such as mefloquine and bedaquiline. Two main objectives were set in this work. Firstly, we evaluated the anti-mycobacterial properties of the previous quinolines 3, which have been identified as good candidates against ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli) bacteria. Secondly, a new series 4 was designed and assessed against the same bacteria strains, taking the pair of enantiomers 3m/3n as the lead. More than twenty compounds 4 were prepared through a five-step asymmetric synthesis with good enantiomeric excesses (>90%). Interestingly, all compounds of series 3 were efficient on M. avium with MIC = 2–16 μg/mL, while series 4 was less active. Both series 3 and 4 were generally more active than mefloquine against the ESKAPEE bacteria. The quinolines 4 were either active against Gram-positive bacteria (MIC ≤ 4 μg/mL for 4c–4h and 4k/4l) or E. coli (MIC = 32–64 μg/mL for 4q–4v) according to the global lipophilicity of these compounds.

A Concise and Highly Enantioselective Total Synthesis of (+)-anti- and (-)-syn-Mefloquine Hydrochloride: Definitive Absolute Stereochemical Assignment of the Mefloquines

Rastelli, Ettore J.,Coltart, Don M.

supporting information, p. 14070 - 14074 (2016/01/25)

A concise asymmetric (>99:1 e.r.) total synthesis of (+)-anti- and (-)-syn-mefloquine hydrochloride from a common intermediate is described. The key asymmetric transformation is a Sharpless dihydroxylation of an olefin that is accessed in three steps from commercially available materials. The Sharpless-derived diol is converted into either a trans or cis epoxide, and these are subsequently converted into (+)-anti- and (-)-syn-mefloquine, respectively. The synthetic (+)-anti- and (-)-syn-mefloquine samples were derivatized with (S)-(+)-mandelic acid tert-butyldimethylsilyl ether, and a crystal structure of each derivative was obtained. These are the first X-ray structures for mefloquine derivatives that were obtained by coupling to a known chiral, nonracemic compound, and provide definitive confirmation of the absolute stereochemistry of (+)-anti- as well as (-)-syn-mefloquine.

4-AMINOALCOHOLQUINOLINE DERIVATIVES, ENANTIOSELECTIVE SYNTHESIS METHODS AND THE USE THEREOF

-

Page/Page column 20-21, (2012/08/28)

The present invention is intended to provide new antimalarial compounds with a strong antimalarial activity as well as antibacterial activity with few neurological side effects and a new enantioselective pathway to mefloquine amino-analogs allowing the access of such compounds. The present invention relates to new 4 -aminoalcohol quinoline derivatives of formula (I), as well as the synthesis methods and the uses of such derivatives. In which Y is one selected from formulae (II) to (III). In which Z is selected from formulae (IV) to (VI), and wherein R1, R2, R3, R4, R5, R6, R7 and n are as defined in the claims.

Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use

-

Page/Page column 12, (2012/08/28)

Mefloquine derivatives, contrary to chloroquine derivatives have not been widely studied to date. Consequently, mefloquine and its derivatives still remain very attractive synthetic targets. Although mefloquine is usually used clinically as a racemic mixture, some studies have shown that its (+)-enantiomer is more potent than the (-)-enantiomer. Moreover, the (-)-enantiomer is responsible for side effects due to reaction with the central nervous system adenosine receptors, while the (+)-enantiomer does no bind at this binding site. Recently, different libraries of racemate 4-aminoalcoholquinolines showed interesting anti-malarial activities. Herein, the present invention describes an enantiopure synthetic and straightforward route to prepare pure enantiomer 4-aminoalcoholquinoline derivatives through the 4-oxirane key-intermediate. A regioselective SN2 ring opening of this epoxide, by diverse amines, allows to obtain the corresponding (R) or (S) 4-aminoquinolines with good yields and enantiomeric excesses generally superior to 92%. The reported methodology appears suitable for the synthesis of a large number of pure enantiomer 4-aminoalcoholquinoline derivatives.

First enantioselective synthesis of 4-aminoalcohol quinoline derivatives through a regioselective SN2 epoxide opening mechanism

Jonet, Alexia,Dassonville-Klimpt, Alexandra,Da Nascimento, Sophie,Leger, Jean-Michel,Guillon, Jean,Sonnet, Pascal

experimental part, p. 138 - 148 (2011/05/02)

Mefloquine derivatives, contrary to chloroquine derivatives have not been widely studied to date. Consequently, mefloquine and its derivatives still remain very attractive synthetic targets. Although mefloquine is usually used clinically as a racemic mixture, some studies have shown that its (+)-enantiomer is more potent than the (-)-enantiomer. Moreover, the (-)-enantiomer is responsible for side effects due to reaction with the central nervous system adenosine receptors, while the (+)-enantiomer does no bind at this binding site. Recently, different libraries of racemic 4-aminoalcohol quinolines showed interesting antimalarial activities. Herein, we describe an enantiopure synthetic and straightforward route to prepare pure enantiomer 4-aminoalcohol quinoline derivatives through a 4-oxirane key-intermediate. A regioselective SN2 ring opening of this epoxide, by diverse amines, allows us to obtain the corresponding (R) or (S) 4-aminoquinolines with good yields and enantiomeric excesses generally superior to 92%. The reported methodology appears suitable for the synthesis of a large number of pure enantiomer 4-aminoalcohol quinoline derivatives.

Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against plasmodium falciparum

Milner, Erin,Gardner, Sean,Moon, Jay,Grauer, Kristina,Auschwitz, Jennifer,Bathurst, Ian,Caridha, Diana,Gerena, Lucia,Gettayacamin, Montip,Johnson, Jacob,Kozar, Michael,Lee, Patricia,Leed, Susan,Li, Qigui,McCalmont, William,Melendez, Victor,Roncal, Norma,Sciotti, Richard,Smith, Bryan,Sousa, Jason,Tungtaeng, Anchalee,Wipf, Peter,Dow, Geoffrey

supporting information; experimental part, p. 6277 - 6285 (2011/11/05)

A library of diamine quinoline methanols were designed based on the mefloquine scaffold. The systematic variation of the 4-position amino alcohol side chain led to analogues that maintained potency while reducing accumulation in the central nervous system (CNS). Although the mechanism of action remains elusive, these data indicate that the 4-position side chain is critical for activity and that potency (as measured by IC90) does not correlate with accumulation in the CNS. A new lead compound, (S)-1-(2,8- bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclopropylamino)ethylamino)ethanol (WR621308), was identified with single dose efficacy and substantially lower permeability across MDCK cell monolayers than mefloquine. This compound could be appropriate for intermittent preventative treatment (IPTx) indications or other malaria treatments currently approved for mefloquine.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 35853-45-3